Biogen Inc vs J B Hunt Transport Services Inc — how do they compare? Biogen Inc trades at $192.5 (market cap $28.34B), while J B Hunt Transport Services Inc trades at $281 (market cap $26.49B). The key difference: Biogen Inc and J B Hunt Transport Services Inc are close in size by market cap, and J B Hunt Transport Services Inc pays a 0.64% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | JBHT | |
|---|---|---|
Market Cap | $28.34B | $26.49B |
Sector | Health | Industrials |
52-Week High | $216.63 | $290.07 |
52-Week Low | $122.68 | $130.65 |
Enterprise Value | $30.62B | $27.78B |
Dividend Yield | — | 0.64% |
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
JB Hunt Transport Services (JBHT) trades at $283.00, up 1.09% with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected soon. Valuation metrics show a P/E of 43.95 and P/S of 2.25, while profitability remains solid with 5.13% net margin and 16.68% ROE. Analyst consensus is strongly positive with 26 buy ratings and a $280.59 price target.
JBHT demonstrates consistent operational performance with stable cash flow generation, though revenue has declined from 2022 peaks. The stock faces valuation concerns with elevated P/E ratios, while freight market cyclicality presents ongoing business risks. Earnings momentum and strong analyst support provide upside potential, but investors should monitor Q2 earnings results for confirmation of growth trajectory.
Trailing returns across standard periods
Latest headlines on both assets
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →